Literature DB >> 1967730

Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.

J D Clemens1, D A Sack, J R Harris, F Van Loon, J Chakraborty, F Ahmed, M R Rao, M R Khan, M Yunus, N Huda.   

Abstract

The protective efficacy (PE) of B subunit killed whole-cell (BS-WC) and killed whole-cell-only (WC) oral cholera vaccines was assessed in a randomised double-blind field trial among children aged 2-15 years and women over 15 years in rural Bangladesh. Among the 62 285 subjects who received three doses of BS-WC, WC, or Escherichia coli K12 strain placebo, cumulative PE at 3 years of follow-up was 50% for BS-WC and 52% for WC. PE was similar against severe and non-severe cholera, but was significantly lower in children who were vaccinated at 2-5 years (26% for BS-WC; 23% for WC) than in older persons (63% for BS-WC; 68% for WC). Among persons vaccinated at 2-5 years, protection at 4-6 months of follow-up was similar to that for older persons, but rapidly waned thereafter and was not evident during the third year of follow-up. In contrast, persons vaccinated at older ages were protected even in the third year of follow-up (PE 40% for BS-WC; 62% for WC). PE was substantially higher against classical cholera (58% for BS-WC; 60% for WC) than against El Tor cholera (39% and 40%).

Entities:  

Keywords:  Asia; Bacterial And Fungal Diseases--prevention and control; Bangladesh; Data Analysis; Delivery Of Health Care; Developing Countries; Diarrhea; Diarrhea, Infantile--prevention and control; Diseases; Evaluation; Examinations And Diagnoses; Health; Health Services; Immunization; Infections; Laboratory Examinations And Diagnoses; Primary Health Care; Research Methodology; Southern Asia; Vaccination

Mesh:

Substances:

Year:  1990        PMID: 1967730     DOI: 10.1016/0140-6736(90)90080-o

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  134 in total

1.  Expanded safety and immunogenicity of a bivalent, oral, attenuated cholera vaccine, CVD 103-HgR plus CVD 111, in United States military personnel stationed in Panama.

Authors:  D N Taylor; J L Sanchez; J M Castro; C Lebron; C M Parrado; D E Johnson; C O Tacket; G A Losonsky; S S Wasserman; M M Levine; S J Cryz
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  Construction of a Vibrio cholerae vaccine candidate using transposon delivery and FLP recombinase-mediated excision.

Authors:  S L Chiang; J J Mekalanos
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

Review 3.  The human, societal, and scientific legacy of cholera.

Authors:  William B Greenough
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

Review 4.  Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens.

Authors:  L Cárdenas; J D Clements
Journal:  Clin Microbiol Rev       Date:  1992-07       Impact factor: 26.132

5.  Cholera: lessons from haiti and beyond.

Authors:  Ana A Weil; Louise C Ivers; Jason B Harris
Journal:  Curr Infect Dis Rep       Date:  2012-02       Impact factor: 3.725

6.  Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh.

Authors:  Daniel T Leung; Mohammad Arif Rahman; M Mohasin; Sweta M Patel; Amena Aktar; Farhana Khanam; Taher Uddin; M Asrafuzzaman Riyadh; Amit Saha; Mohammad Murshid Alam; Fahima Chowdhury; Ashraful Islam Khan; Richelle Charles; Regina LaRocque; Jason B Harris; Stephen B Calderwood; Firdausi Qadri; Edward T Ryan
Journal:  Clin Vaccine Immunol       Date:  2012-03-21

Review 7.  New-generation vaccines against cholera.

Authors:  John Clemens; Sunheang Shin; Dipika Sur; G Balakrish Nair; Jan Holmgren
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-08       Impact factor: 46.802

8.  Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate.

Authors:  F O Eko; D N Okenu; U P Singh; Q He; C Black; J U Igietseme
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

9.  Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine.

Authors:  A Lee; M Chen
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

10.  Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs.

Authors:  C C Häse; L S Thai; M Boesman-Finkelstein; V L Mar; W N Burnette; H R Kaslow; L A Stevens; J Moss; R A Finkelstein
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.